Outlook Therapeutics, Inc. (OTLK)
| Previous Close | 8.92 |
| Open | 8.92 |
| Bid | 8.66 x 100 |
| Ask | 8.88 x 100 |
| Day's Range | 8.87 - 9.12 |
| 52 Week Range | 4.00 - 40.60 |
| Volume | |
| Avg. Volume | 657,149 |
| Market Cap | 206.818M |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.00 |
| Earnings Date | May 13, 2024 - May 17, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 39.91 |
GlobeNewswireOutlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced it will present at the OIS Retina Innovation Showcase being held May 4, 2024 in Seattle, WA. Details for the presentations are as follows: Innovation Showcase: Company PresentationRussell Trenary, President and Chief Exec
Barrons.comMarriott Vacations, Carrols Restaurant Group, and More Stocks See Action From Activist Investors
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
- GlobeNewswire
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
ISELIN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced that it has closed its previously announced private placement with Syntone Ventures, LLC, an existing stockholder, for upfront gross proceeds of approximately $5.0 million from the issuance and sale of shares of the Compa
